---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002960"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2022-03-07T23:59:59+00:00"
generated_at: "2026-06-27T01:12:59.604030+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Rallybio doses first healthy volunteers in Phase 1 study of RLYB116; data expected H2 2022

## Summary
- First healthy volunteers dosed in Phase 1 study of RLYB116.
- Single dose safety, PK, and PD data expected in second half of 2022.
- Corporate presentation updated to reflect Phase 1 milestone and data timeline.

## SEC filing metadata
- accession: 0000950170-22-002960
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2022-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000095017022002960/0000950170-22-002960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000095017022002960/rlyb-20220307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002960
- JSON: https://secwatch.observer/filing/0000950170-22-002960.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.